780 related articles for article (PubMed ID: 27569030)
1. Surface-functionalized, pH-responsive poly(lactic-co-glycolic acid)-based microparticles for intranasal vaccine delivery: Effect of surface modification with chitosan and mannan.
Li Z; Xiong F; He J; Dai X; Wang G
Eur J Pharm Biopharm; 2016 Dec; 109():24-34. PubMed ID: 27569030
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of polyinosinic:polycytidylic acid and flagellin by poly(lactic-
Dai X; He J; Zhang R; Wu G; Xiong F; Zhao B
Int J Nanomedicine; 2017; 12():6617-6632. PubMed ID: 28924346
[TBL] [Abstract][Full Text] [Related]
3. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response.
Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G
ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266
[TBL] [Abstract][Full Text] [Related]
4. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
Jaganathan KS; Vyas SP
Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
Pawar D; Mangal S; Goswami R; Jaganathan KS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of mucoadhesive PLGA microparticles for nasal immunization.
Pawar D; Goyal AK; Mangal S; Mishra N; Vaidya B; Tiwari S; Jain AK; Vyas SP
AAPS J; 2010 Jun; 12(2):130-7. PubMed ID: 20077052
[TBL] [Abstract][Full Text] [Related]
7. PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab.
Elsaid N; Jackson TL; Elsaid Z; Alqathama A; Somavarapu S
Mol Pharm; 2016 Sep; 13(9):2923-40. PubMed ID: 27286558
[TBL] [Abstract][Full Text] [Related]
8. Spray-dried chitosan microparticles for cellular delivery of an antigenic protein: physico-chemical properties and cellular uptake by dendritic cells and macrophages.
Kusonwiriyawong C; Lipipun V; Vardhanabhuti N; Zhang Q; Ritthidej GC
Pharm Res; 2013 Jun; 30(6):1677-97. PubMed ID: 23483441
[TBL] [Abstract][Full Text] [Related]
9. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
Ohashi K; Kabasawa T; Ozeki T; Okada H
J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349
[TBL] [Abstract][Full Text] [Related]
10. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease.
Lautenschläger C; Schmidt C; Lehr CM; Fischer D; Stallmach A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):578-86. PubMed ID: 24084650
[TBL] [Abstract][Full Text] [Related]
11. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine.
Thomas C; Rawat A; Hope-Weeks L; Ahsan F
Mol Pharm; 2011 Apr; 8(2):405-15. PubMed ID: 21189035
[TBL] [Abstract][Full Text] [Related]
12. CS/PAA@TPGS/PLGA nanoparticles with intracellular pH-sensitive sequential release for delivering drug to the nucleus of MDR cells.
Wang YY; Zhang DD; Kong YY; Shao LL; Zhang FY; Gao Y; Mu X; Wang J; Li HF; Yu SQ; Xu Q
Colloids Surf B Biointerfaces; 2016 Sep; 145():716-727. PubMed ID: 27289313
[TBL] [Abstract][Full Text] [Related]
13. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.
Jaganathan KS; Singh P; Prabakaran D; Mishra V; Vyas SP
J Pharm Pharmacol; 2004 Oct; 56(10):1243-50. PubMed ID: 15482638
[TBL] [Abstract][Full Text] [Related]
14. Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.
Dyawanapelly S; Koli U; Dharamdasani V; Jain R; Dandekar P
Drug Deliv Transl Res; 2016 Aug; 6(4):365-79. PubMed ID: 27106502
[TBL] [Abstract][Full Text] [Related]
15. PLGA/DPPC/trimethylchitosan spray-dried microparticles for the nasal delivery of ropinirole hydrochloride: in vitro, ex vivo and cytocompatibility assessment.
Karavasili C; Bouropoulos N; Sygellou L; Amanatiadou EP; Vizirianakis IS; Fatouros DG
Mater Sci Eng C Mater Biol Appl; 2016 Feb; 59():1053-1062. PubMed ID: 26652464
[TBL] [Abstract][Full Text] [Related]
16. Cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses.
Wusiman A; Gu P; Liu Z; Xu S; Zhang Y; Hu Y; Liu J; Wang D; Huang X
Int J Nanomedicine; 2019; 14():3221-3234. PubMed ID: 31123399
[No Abstract] [Full Text] [Related]
17. Microspheres prepared with different co-polymers of poly(lactic-glycolic acid) (PLGA) or with chitosan cause distinct effects on macrophages.
Bitencourt Cda S; Silva LB; Pereira PA; Gelfuso GM; Faccioli LH
Colloids Surf B Biointerfaces; 2015 Dec; 136():678-86. PubMed ID: 26497115
[TBL] [Abstract][Full Text] [Related]
18. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
19. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery.
Parveen S; Sahoo SK
Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969
[TBL] [Abstract][Full Text] [Related]
20. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
